Steven M. Horwitz, MD Associate Attending Memorial Sloan Kettering Cancer Center New York, NY
AMA PRA Category 1 Credit™ Medium
Mobile + Online on Univadis
Non-Hodgkin’s lymphoma (NHL) is the most common hematologic malignancy in adults, and the sixth most common cancer diagnosed in the United States each year. Over the last few decades, new therapies and treatment strategies have significantly improved survival; however, a large proportion of patients are still not cured and many challenges still exist. Patients with NHL, especially those with indolent disease, in particular follicular lymphoma (FL), usually receive multiple therapies over many years. This presents a number of challenges for health care clinicians, including keeping up to date on emerging data on therapies and treatment strategies, as well as managing patients through many years of multiple treatments.
The goal of this continuing education activity is to expand the ability of health care professionals to treat and manage FL, which will improve clinical practice and outcomes. Program Developer/Facilitator
. Target Audience
This educational activity is designed to meet the needs of hematologists, oncologists, and those who manage patients with cancer.
Upon completion of this educational activity, the participant should be able to:
Review recent revisions to NHL treatment guidelines, including updated therapy algorithms.
Review the complications associated with treating patients with NHL.
Review the most current data about new therapies, treatment strategies, and combination regimens for NHL.
It is policy at the Perelman School of Medicine at the University of Pennsylvania for individuals who are in a position to control the content of an educational activity to disclose to the learners all relevant financial relationships that they have with any commercial interest that provides products or services that may be relevant to the content of this continuing medical education activity.
Dr. Horwitz discloses the following relationships with the commercial interests:
Consultant: Allos Therapeutics; Celgene Corporation; Infinity Pharmaceuticals; Kyowa; Millennium Pharmaceuticals, Inc.; Seattle Genetics, Inc.
Grant/Research: Allos Therapeutics; Bristol-Myers Squibb; Celgene Corporation; Genzyme Corporation; Kyowa; Johnson & Johnson; Millennium Pharmaceuticals, Inc.; Seattle Genetics, Inc.
U of Penn Office of CME:
Zalman S. Agus, MD, has no relevant financial relationships to disclose.
Mila Kostic, FACEHP, has no relevant financial relationships to disclose.
Michael Schoen, PhD, has no relevant financial relationships to disclose.
Sara Thier, PhD, MPH, has no relevant financial relationships to disclose.
Investigational and/or Off-Label Use of Commercial Products and Devices: The Perelman School of Medicine at the University of Pennsylvania requires all faculty to disclose any planned discussion of an investigational and/or off-label use of a pharmaceutical product or device within their presentation. Participants should note that the use of products outside FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for approved indications.
In this educational activity, the faculty will not be discussing the investigational use of agents or devices. Credit Statements
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the Perelman School of Medicine at the University of Pennsylvania and MCM Education. The Perelman School of Medicine at the University of Pennsylvania is accredited by the ACCME to provide continuing medical education for physicians.
The Perelman School of Medicine at the University of Pennsylvania designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Release date: May 1, 2013
Last review date: May 1, 2013
Expiration date: April 30, 2014 Commercial Support Statements
Supported by an independent educational grant from Genentech.
* Link to and Log into program on QuantiaMD.com
* Take the pre-test
* Review the activity
* Take the post-test and score 75%
* You are allowed two retakes
* Complete the evaluation
* View, print, or save a CME certificate or certificate of participation verifying your credit/participation in this activity
Computer Requirements: Minimum System Requirements: • Pentium III, 600 MHz or Equivalent Processor • 512 MB of RAM • Windows XP, Vista, or 7 • Mac OS X • 800x600 Monitor Resolution • 16-bit Color • 16 bit Sound Card with Speakers
There is no charge for CME credit.
© 2013, MCM Education. All rights reserved. None of the contents may be reproduced in any form without prior written permission from the publisher. The opinions expressed in this educational activity are those of the faculty and do not necessarily reflect the opinions or recommendations of their affiliated institutions, the publisher, the Perelman School of Medicine at the University of Pennsylvania, or Genentech. Any medications, diagnostic procedures, or treatments discussed by the faculty should not be used by clinicians or other health care professionals without first evaluating their patients’ conditions, considering possible contraindications or risks, reviewing any applicable manufacturer’s product information, and comparing any therapeutic approach with the recommendations of other authorities.